{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:19:57Z","timestamp":1760782797397},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":2731,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1016\/j.ijid.2005.01.003","type":"journal-article","created":{"date-parts":[[2005,9,23]],"date-time":"2005-09-23T13:51:32Z","timestamp":1127483492000},"page":"136-147","source":"Crossref","is-referenced-by-count":8,"title":["Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review"],"prefix":"10.1016","volume":"10","author":[{"given":"Charles M","family":"Fogarty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Aubier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malik","family":"Baz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirkie","family":"van Rensburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manickam","family":"Rangaraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roomi","family":"Nusrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2005.01.003_bib1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00045413-199611000-00004","article-title":"The pharmacoeconomics of respiratory tract infections","volume":"3","author":"Oh","year":"1996","journal-title":"Clin Pulm Med"},{"key":"10.1016\/j.ijid.2005.01.003_bib2","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0149-2918(98)80144-6","article-title":"The cost of treating community-acquired pneumonia","volume":"20","author":"Niederman","year":"1998","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijid.2005.01.003_bib3","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0149-2918(00)88310-1","article-title":"Treatment cost of acute exacerbations of chronic bronchitis","volume":"21","author":"Niederman","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijid.2005.01.003_bib4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0091-6749(99)70464-1","article-title":"Healthcare expenditures for sinusitis in 1996: contributions of asthma, rhinitis, and other airway disorders","volume":"103","author":"Ray","year":"1999","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl. 1A","key":"10.1016\/j.ijid.2005.01.003_bib5","doi-asserted-by":"crossref","first-page":"77S","DOI":"10.1016\/S0002-9343(99)00104-7","article-title":"Therapy for pneumococcal infection at the millennium: doubts and certainties","volume":"107","author":"Ball","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.ijid.2005.01.003_bib6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/313954","article-title":"Practice guidelines for the management of community-acquired pneumonia in adults","volume":"31","author":"Bartlett","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.ijid.2005.01.003_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0924-8579(01)00394-6","article-title":"The clinical impact of macrolide resistance in pneumococcal respiratory infections","volume":"18","author":"Garau","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2005.01.003_bib8","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00019048-199705000-00002","article-title":"IDCP guidelines: management of upper respiratory tract infections","volume":"6","author":"Bartlett","year":"1997","journal-title":"Infect Dis Clin Pract"},{"issue":"Suppl. 36","key":"10.1016\/j.ijid.2005.01.003_bib9","doi-asserted-by":"crossref","first-page":"40s","DOI":"10.1183\/09031936.02.00309002","article-title":"Treatment of community-acquired lower respiratory tract infections in adults","volume":"20","author":"\u00d6rtqvist","year":"2002","journal-title":"Eur Respir J"},{"issue":"Suppl.","key":"10.1016\/j.ijid.2005.01.003_bib10","doi-asserted-by":"crossref","first-page":"43S","DOI":"10.1378\/chest.108.2_Supplement.43S","article-title":"Epidemiology and treatment of chronic bronchitis and its exacerbations","volume":"108","author":"Ball","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.ijid.2005.01.003_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/BF02599141","article-title":"Current diagnosis and management of sinusitis","volume":"9","author":"Willett","year":"1994","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.ijid.2005.01.003_bib12","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM199512143332408","article-title":"Community-acquired pneumonia","volume":"333","author":"Bartlett","year":"1995","journal-title":"N Engl J Med"},{"issue":"6 Suppl.","key":"10.1016\/j.ijid.2005.01.003_bib13","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1067\/mhn.2002.130030","article-title":"Issues in the management of bacterial sinusitis","volume":"127","author":"Bishai","year":"2002","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"Suppl. S1","key":"10.1016\/j.ijid.2005.01.003_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/dkf808","article-title":"Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin","volume":"50","author":"Felmingham","year":"2002","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 2","key":"10.1016\/j.ijid.2005.01.003_bib15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1046\/j.1469-0691.8.s.2.5.x","article-title":"Surveillance of resistance in bacteria causing community-acquired respiratory tract infections","volume":"8","author":"Felmingham","year":"2002","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2005.01.003_bib16","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1128\/AAC.42.8.2138","article-title":"In vitro activities of the ketolide HMR 3647 against recent Gram-positive clinical isolates and Haemophilus influenzae","volume":"42","author":"Barry","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2005.01.003_bib17","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1128\/AAC.42.11.3032","article-title":"Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and Moraxella catarrhalis by MIC determination and time-kill assay","volume":"42","author":"Pankuch","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2005.01.003_bib18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1128\/AAC.42.6.1515","article-title":"In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae","volume":"42","author":"Roblin","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2005.01.003_bib19","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1128\/AAC.42.6.1520","article-title":"Susceptibilities of Legionella spp. to newer antimicrobials in vitro","volume":"42","author":"Sch\u00fclin","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2005.01.003_bib20","unstructured":"Fogarty C, Patel TC, Galbraith H, et al. Efficacy of the first ketolide antibacterial, telithromycin, in the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae [Abstract 857]. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, December 16\u201319, 2001. Washington, DC: American Society for Microbiology; 2001. p. 449."},{"key":"10.1016\/j.ijid.2005.01.003_bib21","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/rmed.2002.1382","article-title":"Telithromycin is as effective as amoxicillin\/clavulanate in acute exacerbations of chronic bronchitis","volume":"96","author":"Aubier","year":"2002","journal-title":"Respir Med"},{"key":"10.1016\/j.ijid.2005.01.003_bib22","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s15010-002-2096-z","article-title":"Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for the treatment of community-acquired pneumonia","volume":"30","author":"Hagberg","year":"2002","journal-title":"Infection"},{"key":"10.1016\/j.ijid.2005.01.003_bib23","first-page":"883","article-title":"Efficacy of short-course therapy with the ketolide telithromycin compared with 10 days of penicillin V for the treatment of pharyngitis\/tonsillitis","volume":"33","author":"Norrby","year":"2002","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijid.2005.01.003_bib24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000057670","article-title":"Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis","volume":"48","author":"Roos","year":"2002","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijid.2005.01.003_bib25","unstructured":"Tellier G, Isakov T, Patel M, et al. Efficacy and safety of telithromycin (800mg once daily) for 5 or 7 days vs. clarithromycin (500mg twice daily) for 10 days in the treatment of patients with community-acquired pneumonia [Abstract L-373]. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA, September 27\u201330, 2002. Washington, DC: American Society for Microbiology; 2002. p. 346."},{"key":"10.1016\/j.ijid.2005.01.003_bib26","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1185\/030079902125001191","article-title":"Efficacy and safety of telithromycin in community acquired pneumonia","volume":"18","author":"van Rensburg","year":"2002","journal-title":"Curr Opin Med Res"},{"key":"10.1016\/j.ijid.2005.01.003_bib27","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/194589240301700610","article-title":"A comparison of the efficacy of telithromycin vs. cefuroxime axetil in the treatment of acute maxillary sinusitis","volume":"17","author":"Buchanan","year":"2003","journal-title":"Am J Rhinol"},{"key":"10.1016\/j.ijid.2005.01.003_bib28","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1046\/j.1469-0691.2003.00678.x","article-title":"Efficacy of telithromycin, a new once-daily ketolide antimicrobial, in the treatment of community-acquired pneumonia","volume":"9","author":"Carbon","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2005.01.003_bib29","unstructured":"Fogarty C, de Wet R, Nusrat R. Five-day telithromycin is as effective as 10-day clarithromycin in the treatment of acute exacerbations of chronic bronchitis [Abstract 2230]. In: Abstracts of the 13th Annual Congress of the European Respiratory Society, Vienna, Austria, September 27\u2013October 1, 2003. Eur Respir J 2003; 22(Suppl. 45):351s."},{"key":"10.1016\/j.ijid.2005.01.003_bib30","doi-asserted-by":"crossref","unstructured":"Luterman M, Tellier G, Lasko B, Leroy B. Efficacy and tolerability of telithromycin for 5 or 10 days vs. amoxicillin\/clavulanic acid for 10 days in the treatment of acute maxillary sinusitis. Ear Nose Throat J 2003;82:576\u201380, 582\u20134, 586 passim.","DOI":"10.1177\/014556130308200812"},{"key":"10.1016\/j.ijid.2005.01.003_bib31","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1742-1241.2003.tb10511.x","article-title":"Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults","volume":"57","author":"Pullman","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ijid.2005.01.003_bib32","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0149-2918(03)80087-5","article-title":"Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-hemolytic streptococcal tonsillitis\/pharyngitis: a multicenter, randomized, double-blind, parallel-group study","volume":"25","author":"Quinn","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijid.2005.01.003_bib33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/147323000303100301","article-title":"Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis","volume":"31","author":"Zervos","year":"2003","journal-title":"J Int Med Res"},{"key":"10.1016\/j.ijid.2005.01.003_bib34","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0149-2918(04)90005-7","article-title":"Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults","volume":"26","author":"Dunbar","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijid.2005.01.003_bib35","unstructured":"Fogarty C, van Rensburg D, De Salvo C, Rangaraju M, Nusrat R. Efficacy of a 7-day course of oral telithromycin 800mg once daily in community-acquired pneumonia caused by resistant Streptococcus pneumoniae. Abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases, May 1\u20134 2004. Prague, Czech Republic."},{"key":"10.1016\/j.ijid.2005.01.003_bib36","series-title":"Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved standard","author":"National Committee for Clinical Laboratory Standards","year":"2000"},{"key":"10.1016\/j.ijid.2005.01.003_bib37","series-title":"Performance Standards for Antimicrobial Disk Susceptibility Tests; 11th informational M100-S11","author":"National Committee for Clinical Laboratory Standards","year":"2001"},{"issue":"Suppl. 4","key":"10.1016\/j.ijid.2005.01.003_bib38","first-page":"1","article-title":"Guidelines for the management of community-acquired pneumonia in adults","volume":"56","author":"British Thoracic Society","year":"2001","journal-title":"Thorax"},{"key":"10.1016\/j.ijid.2005.01.003_bib39","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","article-title":"Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention","volume":"163","author":"Niederman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2005.01.003_bib40","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1053\/srin.2000.18077","article-title":"Antibiotic therapy in acute exacerbations of chronic bronchitis","volume":"15","author":"Adams","year":"2000","journal-title":"Semin Respir Infect"},{"issue":"8 Suppl.","key":"10.1016\/j.ijid.2005.01.003_bib41","first-page":"S427","article-title":"The role of infection in acute exacerbations of chronic obstructive airways disease","volume":"6","author":"Hillberg","year":"2000","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.ijid.2005.01.003_bib42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/srin.2000.0150059","article-title":"Antibiotic therapy of exacerbations of chronic bronchitis","volume":"15","author":"Niederman","year":"2000","journal-title":"Semin Respir Infect"},{"key":"10.1016\/j.ijid.2005.01.003_bib43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1067\/mhn.2000.107873","article-title":"Antimicrobial treatment guidelines for acute bacterial rhinosinusitis","volume":"123","author":"Sinus and Allergy Health Partnership","year":"2000","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ijid.2005.01.003_bib44","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/jac\/dkg153","article-title":"Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin","volume":"51","author":"Fogarty","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2005.01.003_bib45","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1053\/rmed.2003.1492","article-title":"Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis","volume":"97","author":"Hagberg","year":"2003","journal-title":"Respir Med"},{"key":"10.1016\/j.ijid.2005.01.003_bib46","unstructured":"Low DE, Felmingham D, Rangaraju M, Nusrat R. Potent activity of telithromycin in the treatment of key respiratory pathogens associated with community-acquired upper and lower respiratory tract infections [Abstract P1128]. 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, UK, May 10\u201313, 2003. Clin Microbiol Infect 2003; 9(Suppl. 1):267."},{"key":"10.1016\/j.ijid.2005.01.003_bib47","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s15010-003-3142-1","article-title":"A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults","volume":"31","author":"Carbon","year":"2003","journal-title":"Infection"},{"issue":"Suppl. A","key":"10.1016\/j.ijid.2005.01.003_bib48","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0954-6111(01)90022-8","article-title":"Clinical failures: the tip of the iceberg?","volume":"95","author":"Garau","year":"2001","journal-title":"Respir Med"},{"key":"10.1016\/j.ijid.2005.01.003_bib49","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1086\/341978","article-title":"Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae","volume":"35","author":"Lonks","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2005.01.003_bib50","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1086\/318157","article-title":"Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin","volume":"31","author":"Kelley","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2005.01.003_bib51","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/00006454-199611000-00026","article-title":"Breakthrough sepsis in macrolide-resistant pneumococcal infection","volume":"15","author":"Jackson","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijid.2005.01.003_bib52","unstructured":"Garau J, Lonks JR, Gomez L, et al. Failure of macrolide therapy in patients with bacteremia due to macrolide resistant Streptococcus pneumoniae [Abstract 7.09]. In: Abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, Seville, Spain, January 26\u201328, 2000. Georgia, PA: ICMAS Inc.; 2000. p. 65."},{"key":"10.1016\/j.ijid.2005.01.003_bib53","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1378\/chest.118.6.1839-a","article-title":"Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy","volume":"118","author":"Waterer","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.ijid.2005.01.003_bib54","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJM200202213460820","article-title":"Emergence of macrolide resistance during treatment of pneumococcal pneumonia","volume":"346","author":"Musher","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2005.01.003_bib55","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/jac\/dkg116","article-title":"Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral \u03b2-lactams","volume":"51","author":"Van Kerkhoven","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2005.01.003_bib56","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1086\/313976","article-title":"Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin","volume":"31","author":"Fogarty","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2005.01.003_bib57","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0732-8893(02)00379-6","article-title":"Azithromycin treatment failure in community-acquired pneumonia caused by Streptococcus pneumoniae resistant to macrolides by a 23S rRNA mutation","volume":"43","author":"Kays","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2005.01.003_bib58","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1001\/jama.286.15.1857","article-title":"Macrolide resistance among invasive Streptococcus pneumoniae isolates","volume":"286","author":"Hyde","year":"2001","journal-title":"JAMA"},{"issue":"Suppl. 3","key":"10.1016\/j.ijid.2005.01.003_bib59","first-page":"7","article-title":"Structure\u2013activity relationships of ketolides vs. macrolides","volume":"7","author":"Douthwaite","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2005.01.003_bib60","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/jac\/47.6.837","article-title":"Lung concentrations of telithromycin after oral dosing","volume":"47","author":"Khair","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2005.01.003_bib61","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1128\/AAC.45.11.3104-3108.2001","article-title":"Bronchopulmonary disposition of the ketolide antimicrobial, telithromycin (HMR 3647)","volume":"45","author":"Muller-Serieys","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2005.01.003_bib62","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/jama.1996.03530260048030","article-title":"Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis","volume":"275","author":"Fine","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2005.01.003_bib63","first-page":"227","article-title":"Pneumococcal pneumonia: epidemiology and clinical features","volume":"14","author":"Marrie","year":"1999","journal-title":"Semin Respir Infect"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971205000354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971205000354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T19:09:58Z","timestamp":1683227398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971205000354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S1201971205000354"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2005.01.003","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}